Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alfa-2b for high-risk melanoma patients using intergroup clinical trial data

Journal of Clinical Oncology

Volumn 20, Issue 5, 2002, Pages 1311-1318

  Kilbridge, Kerry Laing ^a   Cole, Bernard F ^a   Kirkwood, John M ^a   Haluska, Frank G ^a   Atkins, Michael A ^a   Ruckdeschel, John C ^a   Sock, Dana E ^a   Nease Jr , Robert F ^a   Weeks, Jane C ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

CHEMOTHERAPY, ADJUVANT; HUMANS; INTERFERON ALFA-2B; MELANOMA; PATIENT SATISFACTION; QUALITY OF LIFE; SKIN NEOPLASMS;

EID: 0036499079     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.5.1311     Document Type: Article

References (29)

1. A new American Joint Committee on Cancer staging system for cutaneous melanoma
2. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system
3. Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients
4. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684
5. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: An Eastern Cooperative Oncology Group study
6. A clinician's guide to utility measurement
7. Patient preferences for adjuvant interferon alfa-2b treatment
8. High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190
9. A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer
10. A quality-of-life-oriented endpoint for comparing therapies
11. Quality adjusted survival analysis
12. Evaluation of effectiveness: Q-TWiST - The International Breast Cancer Study Group
13. Nonparametric estimation from incomplete observations
14. On a test of whether one or two random variables is stochastically larger than the other
15. Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer: The International Breast Cancer Study Group
16. A quality-adjusted survival meta-analysis of adjuvant chemotherapy for premenopausal breast cancer: International Breast Cancer Study Group
17. Quality-of-life evaluation in a clinical trial of zidovudine therapy in patients with mildly symptomatic HIV infection: The AIDS Clinical Trials Group
18. Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection: The AIDS Clinical Trials Group
19. Cancer patients, doctors and nurses vary in their willingness to undertake cancer chemotherapy
20. Who shall decide?
21. Sex or survival: Trade-offs between quality and quantity of life
22. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: Descriptive study based on scripted interviews
23. Perceptions of cancer patients and their physicians involved in phase I trials
24. Phase I trials in pediatric oncology: Perceptions of pediatricians from the United Kingdom Children's Cancer Study Group and the Pediatric Oncology Group
25. Patient preferences concerning the trade-off between the risks and benefits of routine radiation therapy after conservative surgery for early-stage breast cancer
26. Expectations and experiences of patients with cancer participating in phase I clinical trials
27. Whose values in CEA? The impact of anticipated adaptation
28. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIb-III melanoma: Results of Intergroup Trial E1694/S9512/C509801